Minsk, Belarus, 18 April 2021— The Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent System (“Firehawk Liberty™”), developed by Shanghai MicroPort Medical Group Co., Ltd. (MicroPort®), has received registration approval from the Ministry of Health of Belarus.
Firehawk LibertyTM is a drug-eluding stent (DES) that features strut in-groove coating and precision target drug-releasing patent technology. It utilizes innovative stent balloon technology to optimize expansion performance, offering better crossability, traceability and pushability, and thus further optimizing the vessel wall apposition of the stent.
With nearly 600 grooves evenly cut in the hair-thin but extremely hard CoCr alloy, Firehawk LibertyTM combines the advantages of both the bare metal stent and drug-eluting stent. The stent allows for the precise injection of drugs into the micro-grooves by means of a fully automatic 3D-printed micro-groove filling, ensuring the effectiveness of the drug whilst significantly reducing the drug loading.
The approval of Firehawk Liberty™ has broadened the coronary intervention product line of MicroPort® in Belarus, further expanding the global footprint of MicroPort® medical products. In the future, MicroPort® aims to continue introducing more high quality and innovative medical devices to overseas markets, so as to offer a complete medical solution for patients around the world.
About Shanghai MicroPort Medical Group Co., Ltd
Shanghai MicroPort Medical Group Co., Ltd. (MicroPort®) is a subsidiary of MicroPort Scientific Corporation (00853.HK). MicroPort® has grown over the years to become one of the leading manufacturers of medical devices. Its products cover a wide range of medical fields, including cardio rhythm management, orthopedic devices, vascular intervention, surgical management, and more. As a leader in high-end innovative medical solutions, MicroPort® places emphasis on the human dimension while integrating the pursuit of perfection and innovation into the corporate DNA.